{"success":true,"data":{"pressRelease":{"id":"132737","rtpr_id":"nPn4K1hF8a","ticker":"BMRN","exchange":"NASDAQ","all_tickers":["BMRN"],"title":"BioMarin Announces Close of the Alesta Therapeutics Acquisition","author":"PR Newswire","published_at":"2026-09-01T13:05:01.638Z","article_body":"BioMarin Announces Close of the Alesta Therapeutics Acquisition\n\nPR Newswire\n\nSAN RAFAEL, Calif., Sept. 1, 2026\n\nAcquisition adds ALE1, a potential first oral therapy for hypophosphatasia to\nclinical pipeline\n\nSAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc.\n(Nasdaq: BMRN) said today that it completed the previously announced agreement\nto acquire Alesta Therapeutics. The acquisition will strengthen BioMarin's\nskeletal conditions portfolio, adding ALE1, an oral small molecule for the\npotential treatment of hypophosphatasia (HPP), a rare genetic bone disease\ncaused by mutations in the ALPL gene. ALE1 is currently being evaluated in an\nongoing Phase 1/2a clinical trial assessing safety, tolerability and\npharmacokinetics/pharmacodynamics in healthy volunteers and adults with HPP.\n\nOn August 18, BioMarin announced it had entered into a definitive agreement to\nacquire Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1.\nPrior to the close of the transaction, Alesta spun out all non-ALE1 assets to\na new entity. Alesta Therapeutics is now a wholly owned subsidiary of\nBioMarin.\n\nAbout BioMarin\nBioMarin is a leading, global rare disease biotechnology company focused on\ndelivering medicines for people living with genetically defined conditions.\nFounded in 1997, the San Rafael, California-based company has a proven track\nrecord of innovation, with nine commercial therapies and a strong clinical and\npreclinical pipeline. Using a distinctive approach to drug discovery and\ndevelopment, BioMarin seeks to unleash the full potential of genetic science\nby pursuing category-defining medicines that have a profound impact on\npatients.\n\nTo learn more, please visit www.biomarin.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764231-1&h=2289745515&u=https%3A%2F%2Fwww.biomarin.com%2F&a=www.biomarin.com)\n.\n\nAbout Alesta Therapeutics\nAlesta Therapeutics is a clinical-stage biotechnology company committed to\ndeveloping novel oral small-molecule therapies for underserved diseases. The\ncompany's lead asset, ALE1, is being developed for hypophosphatasia (HPP), a\nrare genetic disorder with significant unmet need.\n\nFor more information, visit www.alestatherapeutics.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764231-1&h=3028261183&u=http%3A%2F%2Fwww.alestatherapeutics.com%2F&a=www.alestatherapeutics.com)\n.\n\nForward-Looking Statements\nThis press release contains forward-looking statements about, among other\nthings, the acquisition of ALE1, the lead clinical-stage asset, of Alesta\nTherapeutics (Alesta) by BioMarin Pharmaceutical Inc. (BioMarin) and the\nbusiness prospects of BioMarin, including, without limitation, statements\nabout: the prospective benefits of the acquisition, including expectations\nthat it will strengthen BioMarin's skeletal conditions portfolio; expectations\nregarding ALE1 and its ongoing development, including its potential to be a\nfirst-in-class oral therapy for the treatment of hypophosphatasia (HPP); and\nother statements that are not historical facts.\n\nThese forward-looking statements are predictions and involve risks and\nuncertainties such that actual results may differ materially from these\nstatements. These risks and uncertainties include, among others: the effects\nof the acquisition (or the announcement thereof) on BioMarin's stock price\nand/or BioMarin's operating results; unknown or inestimable liabilities;\nBioMarin's ability to successfully develop, launch and commercialize products\nand product candidates such as ALE1, if approved; BioMarin's ability to\nrealize the anticipated benefits of the acquisition, including the possibility\nthat the expected benefits from the acquisition will not be realized or will\nnot be realized within the expected time period and that integration will not\nbe successful or that such integration may be more difficult, time-consuming\nor costly than expected; the time-consuming and uncertain regulatory approval\nprocess for pharmaceutical product development; the costly and time-consuming\npharmaceutical product development process and the uncertainty of clinical\nsuccess, including risks related to failure or delays in successfully\ninitiating or completing clinical trials and assessing patients, including\nwith respect to current and planned future clinical trials; and those factors\ndetailed in BioMarin's filings with the Securities and Exchange Commission,\nincluding, without limitation, the factors contained under the caption \"Risk\nFactors\" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended\nJune 30, 2026, as such factors may be updated by any subsequent reports.\nInvestors are urged not to place undue reliance on forward-looking statements,\nwhich speak only as of the date hereof. BioMarin is under no obligation, and\nexpressly disclaims any obligation to update or alter any forward-looking\nstatement, whether as a result of new information, future events or otherwise.\n\nBioMarin(®) is a registered trademark of BioMarin Pharmaceutical Inc. or its\naffiliates.\n Contacts:\n\n Investors                     Media\n Traci McCarty                 Erin Rau\n BioMarin Pharmaceutical Inc.   BioMarin Pharmaceutical Inc.\n (415) 455-7558                 (925) 683-9622\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/biomarin-announces-close-of-the-alesta-therapeutics-acquisition-302865598.html\n(https://www.prnewswire.com/news-releases/biomarin-announces-close-of-the-alesta-therapeutics-acquisition-302865598.html)\n\nSOURCE BioMarin Pharmaceutical Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS776208/BioMarin-Pharmaceutical-Inc-Logo.jpg?id=OA2921527\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn4K1hF8a","title":"BioMarin Announces Close of the Alesta Therapeutics Acquisition","author":"PR Newswire","ticker":"BMRN","created":"2026-09-01T13:05:01.638Z","tickers":["BMRN"],"exchange":"NASDAQ","article_body":"BioMarin Announces Close of the Alesta Therapeutics Acquisition\n\nPR Newswire\n\nSAN RAFAEL, Calif., Sept. 1, 2026\n\nAcquisition adds ALE1, a potential first oral therapy for hypophosphatasia to\nclinical pipeline\n\nSAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc.\n(Nasdaq: BMRN) said today that it completed the previously announced agreement\nto acquire Alesta Therapeutics. The acquisition will strengthen BioMarin's\nskeletal conditions portfolio, adding ALE1, an oral small molecule for the\npotential treatment of hypophosphatasia (HPP), a rare genetic bone disease\ncaused by mutations in the ALPL gene. ALE1 is currently being evaluated in an\nongoing Phase 1/2a clinical trial assessing safety, tolerability and\npharmacokinetics/pharmacodynamics in healthy volunteers and adults with HPP.\n\nOn August 18, BioMarin announced it had entered into a definitive agreement to\nacquire Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1.\nPrior to the close of the transaction, Alesta spun out all non-ALE1 assets to\na new entity. Alesta Therapeutics is now a wholly owned subsidiary of\nBioMarin.\n\nAbout BioMarin\nBioMarin is a leading, global rare disease biotechnology company focused on\ndelivering medicines for people living with genetically defined conditions.\nFounded in 1997, the San Rafael, California-based company has a proven track\nrecord of innovation, with nine commercial therapies and a strong clinical and\npreclinical pipeline. Using a distinctive approach to drug discovery and\ndevelopment, BioMarin seeks to unleash the full potential of genetic science\nby pursuing category-defining medicines that have a profound impact on\npatients.\n\nTo learn more, please visit www.biomarin.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764231-1&h=2289745515&u=https%3A%2F%2Fwww.biomarin.com%2F&a=www.biomarin.com)\n.\n\nAbout Alesta Therapeutics\nAlesta Therapeutics is a clinical-stage biotechnology company committed to\ndeveloping novel oral small-molecule therapies for underserved diseases. The\ncompany's lead asset, ALE1, is being developed for hypophosphatasia (HPP), a\nrare genetic disorder with significant unmet need.\n\nFor more information, visit www.alestatherapeutics.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4764231-1&h=3028261183&u=http%3A%2F%2Fwww.alestatherapeutics.com%2F&a=www.alestatherapeutics.com)\n.\n\nForward-Looking Statements\nThis press release contains forward-looking statements about, among other\nthings, the acquisition of ALE1, the lead clinical-stage asset, of Alesta\nTherapeutics (Alesta) by BioMarin Pharmaceutical Inc. (BioMarin) and the\nbusiness prospects of BioMarin, including, without limitation, statements\nabout: the prospective benefits of the acquisition, including expectations\nthat it will strengthen BioMarin's skeletal conditions portfolio; expectations\nregarding ALE1 and its ongoing development, including its potential to be a\nfirst-in-class oral therapy for the treatment of hypophosphatasia (HPP); and\nother statements that are not historical facts.\n\nThese forward-looking statements are predictions and involve risks and\nuncertainties such that actual results may differ materially from these\nstatements. These risks and uncertainties include, among others: the effects\nof the acquisition (or the announcement thereof) on BioMarin's stock price\nand/or BioMarin's operating results; unknown or inestimable liabilities;\nBioMarin's ability to successfully develop, launch and commercialize products\nand product candidates such as ALE1, if approved; BioMarin's ability to\nrealize the anticipated benefits of the acquisition, including the possibility\nthat the expected benefits from the acquisition will not be realized or will\nnot be realized within the expected time period and that integration will not\nbe successful or that such integration may be more difficult, time-consuming\nor costly than expected; the time-consuming and uncertain regulatory approval\nprocess for pharmaceutical product development; the costly and time-consuming\npharmaceutical product development process and the uncertainty of clinical\nsuccess, including risks related to failure or delays in successfully\ninitiating or completing clinical trials and assessing patients, including\nwith respect to current and planned future clinical trials; and those factors\ndetailed in BioMarin's filings with the Securities and Exchange Commission,\nincluding, without limitation, the factors contained under the caption \"Risk\nFactors\" in BioMarin's Quarterly Report on Form 10-Q for the quarter ended\nJune 30, 2026, as such factors may be updated by any subsequent reports.\nInvestors are urged not to place undue reliance on forward-looking statements,\nwhich speak only as of the date hereof. BioMarin is under no obligation, and\nexpressly disclaims any obligation to update or alter any forward-looking\nstatement, whether as a result of new information, future events or otherwise.\n\nBioMarin(®) is a registered trademark of BioMarin Pharmaceutical Inc. or its\naffiliates.\n Contacts:\n\n Investors                     Media\n Traci McCarty                 Erin Rau\n BioMarin Pharmaceutical Inc.   BioMarin Pharmaceutical Inc.\n (415) 455-7558                 (925) 683-9622\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/biomarin-announces-close-of-the-alesta-therapeutics-acquisition-302865598.html\n(https://www.prnewswire.com/news-releases/biomarin-announces-close-of-the-alesta-therapeutics-acquisition-302865598.html)\n\nSOURCE BioMarin Pharmaceutical Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS776208/BioMarin-Pharmaceutical-Inc-Logo.jpg?id=OA2921527\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-01T13:05:01.713081592Z","server_sent_at_ms":1788267901713},"received_at":"2026-09-01T13:05:01.798Z","source_url":"https://www.prnewswire.com/news-releases/biomarin-announces-close-of-the-alesta-therapeutics-acquisition-302865598.html"},"analysis":{"id":"121635","press_release_id":"132737","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Deal value not disclosed in release","Acquired asset is early-stage (Phase 1/2a)"],"eventType":"m_and_a","narrative":"BioMarin completed its acquisition of Alesta Therapeutics, adding the oral small molecule ALE1 to its clinical pipeline for the treatment of hypophosphatasia (HPP).\n\nALE1 is a potential first-in-class therapy currently in a Phase 1/2a trial assessing safety and tolerability in healthy volunteers and adults with HPP.\n\nPrior to the close, Alesta spun out all non-ALE1 assets to a new entity, leaving BioMarin with the skeletal condition asset as a wholly owned subsidiary.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"BioMarin bolsters rare bone disease pipeline with completed Alesta acquisition."},"keyFigures":{"drugName":"ALE1","phaseOfTrial":"Phase 1/2a"},"quotedText":"","namedEntities":{"people":[],"products":["ALE1"],"companies":[{"name":"BioMarin Pharmaceutical Inc.","ticker":"BMRN"},{"name":"Alesta Therapeutics","relationship":"acquired"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Completed acquisition of Alesta Therapeutics adds ALE1, a potential first-in-class oral therapy for hypophosphatasia, strengthening BioMarin's skeletal conditions portfolio and expanding its rare disease pipeline."},"tickerRelevance":{"others":[],"primary":"BMRN"},"globalImportance":25,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid_cap_biotech","eventGravity":"acquisition_close","sectorWeight":"rare_disease"}},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"BioMarin completed its acquisition of Alesta Therapeutics, adding the oral small molecule ALE1 to its clinical pipeline for the treatment of hypophosphatasia (HPP).\n\nALE1 is a potential first-in-class therapy currently in a Phase 1/2a trial assessing safety and tolerability in healthy volunteers and adults with HPP.\n\nPrior to the close, Alesta spun out all non-ALE1 assets to a new entity, leaving BioMarin with the skeletal condition asset as a wholly owned subsidiary.","key_figures":{"drugName":"ALE1","phaseOfTrial":"Phase 1/2a"},"named_entities":{"people":[],"products":["ALE1"],"companies":[{"name":"BioMarin Pharmaceutical Inc.","ticker":"BMRN"},{"name":"Alesta Therapeutics","relationship":"acquired"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-01T16:18:57.273Z","global_importance":25,"audience_relevance":35,"importance_components":{"tickerTier":"mid_cap_biotech","eventGravity":"acquisition_close","sectorWeight":"rare_disease"}},"durationMs":384179,"modelName":"glm-4.7"}}